Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Pasi A. Jänne(Dana-Farber Cancer Institute), Alice T. Shaw(Massachusetts General Hospital), José Rodrigues Pereira(Instituto Brasileiro de Controle do Câncer), G. Jeannin, Johan Vansteenkiste, Carlos H. Barrios(Pontifícia Universidade Católica do Rio Grande do Sul), Fábio Franke(Hospital Universitário Cajuru), Lynda Grinsted(AstraZeneca (United Kingdom)), Victoria Zazulina(AstraZeneca (United Kingdom)), Paul D. Smith(AstraZeneca (United Kingdom)), Ian C. P. Smith(AstraZeneca (United Kingdom)), Lucio Crinò
The Lancet Oncology
November 27, 2012
Cited by 657

Abstract


Related Papers

No related papers found

Powered by citation graph analysis